Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc., trading under the ticker AMHC, is a clinical-stage biotechnology company that reached public markets through a business combination with Amplitude Healthcare Acquisition Corporation, a blank-check company sponsored by Amplitude Healthcare Sponsor, LLC, which completed its SPAC IPO in 2021. The company operates in the biotechnology and hematopoietic stem cell therapeutics sector, with a pipeline targeting severe allergic diseases and conditioning regimens for stem cell transplantation. The DEF 14A proxy statement filed on September 4, 2026, under accession number 0001213900-26-097572, represents the company's definitive proxy solicitation to shareholders. Visit SpacDesk and sign up for full data, filings history, and real-time analytics on Jasper Therapeutics and hundreds of other SPAC-linked companies.